MarketWatch (press release) Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused ... and more »
DailyFinance UCERIS ( budesonide ) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are ...
StreetInsider.com (subscription) Received FDA approval in January 2013 of UCERIS ( budesonide ) extended release tablets 9 mg for the induction of remission in patients with active, mild to moderate ulcerative colitis. The company began promoting UCERIS to gastroenterologists during the ...
Seeking Alpha Our sale representatives tell us that physical view UCERIS as familiar and logical treatment approach combing budesonide , a drug they're comfortable with and know with the MMX colonic delivery technology. Our feedback from doctors reinforces the clear ...
Seeking Alpha During the first quarter of 2013, the company also continued to make progress in the development of budesonide foam. We anticipate top line data from our 2 budesonide foam Phase III trials by the end of May 2013. Currently, we are targeting submission ... and more »
WKZO Breo would also compete with AstraZeneca Plc's twice-a-day Symbicort, an inhaled combination of the corticosteroid budesonide , and the long-acting beta-agonist formoterol. Glaxo and Theravance are hoping the once-daily delivery of Breo will make their ... and more »
DailyFinance Santarus re-launched ZEGERID ( omeprazole /sodium bicarbonate) with promotion to gastroenterologists and other selected physicians in February 2013. ZEGERID prescriptions have been significantly impacted by generic competition and lack of promotion ... and more »
PMLiVE GSK isn't the only company looking to make the most of an increasing respiratory market, and other companies to get in on the act include AstraZeneca, which has already gained approval for the use of Symbicort ( budesonide /formoterol) in treating COPD.
Seeking Alpha As for budesonide (for the treatment of eosinophilic esophagitis), ViroPharma has indicated that Phase II data will be available in 2014. As a reminder, budesonide is exclusively licensed to ViroPharma by Meritage Pharm (privately held), and ViroPharma ...
